Transfusion Reactions Associated with COVID-19 Convalescent Plasma Therapy for SARS-CoV-2.

CONCLUSION: Our findings support the use of CP as a safe therapeutic option from a transfusion reaction perspective, in the setting of COVID-19. Further studies are needed to confirm the clinical significance of ABO group B, age, and predisposing disease severity in the incidence of transfusion reaction events.
PMID: 33125158 [PubMed - as supplied by publisher]

Source: Transfusion - October 30, 2020 Category: Hematology Authors: Nguyen FT, van den Akker T, Lally K, Lam H, Lenskaya V, Liu STH, Bouvier NM, Aberg JA, Rodriguez D, Krammer F, Strauss D, Shaz BH, Rudon L, Galdon P, Jhang JS, Arinsburg SA, Baine I, Mount Sinai Health System Convalescent Plasma Team Tags: Transfusion Source Type: research